Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade

Reference:
Size

,

Brand

Product type

Clonality

Expression system

Description of Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb - Research Grade

Description of Sotrovimab Biosimilar - Anti-Spike glycoprotein mAb - Research Grade

About Sotrovimab biosimilar

Sotrovimab is a neutralizing monoclonal antibody with an activity against SARS-CoV-2 virus in humans. It has been commercialized as XEVUDY by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is able to bind with Spike protein, which is responsible of the pathogenicity of the Severe Acute Respiratory Syndrome- Coronavirus( SARS-CoV-2).

A treatment by biosimilar recently approved

FDA and EMA have very recently given their approvals for the marketing of Sotrovimab as a treatment against some severe forms of COVID. The epitope targeted by this neutralizing antibody is not mutated in the different variants of SARS-CoV-2 of concern.

About Spike protein

Spike glycoprotein is a transmembrane viral fusion protein. It is known to be paramount in the binding of the virus to the cell during infection process. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.

A research grade biosimilar

Sotrovimab biosimilar is a dual-action antibody, which is able to to neutralize the virus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs. Proteogenix offers this product for research use only. Sotrovimab is a human-origin monoclonal antibody expressed in a mammalian system (Chinese Hamster Ovaries-CHO).

Product nameSotrovimab Biosimilar - Anti-Spike glycoprotein mAb - Research Grade
SpeciesHumanized
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
ReferencePX-TA1637
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeHuman IgG
ClonalityMonoclonal Antibody
Product nameSotrovimab Biosimilar - Anti-Spike glycoprotein mAb - Research Grade
SpeciesHumanized
Expression systemMammalian cells
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
ReferencePX-TA1637
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeHuman IgG
ClonalityMonoclonal Antibody

1 review for Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade

  1. Toshi

    This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody did not show weak inhibition of all variants tested (IC50 344.03 ng/mL for Delta, >500 ng/mL for Gamma and Alpha, 244.1 ng/mL for the wild type).

Add a review

Your email address will not be published.


Clear
OK

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us

Categories: